12:00 AM
 | 
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Afinitor everolimus: Phase III data

Last year, the European Commission approved Afinitor in combination with Aromasin exemestane to treat postmenopausal women with hormone receptor-positive, HER2-negative breast cancer that has progressed after treatment with a non-steroidal aromatase inhibitor. In the U.S., the drug is approved in combination with Aromasin to treat postmenopausal women with hormone receptor-positive/HER2-negative breast cancer that has progressed after treatment with the pharma's Femara letrozole or Arimidex anastrozole.

Novartis also markets everolimus as Afinitor in the U.S. and EU to treat advanced renal cell carcinoma (RCC), neuroendocrine tumors of...

Read the full 451 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >